FDA grants orphan status to new ALS drug candidate PAS-004
Original source
FDA grants orphan status to new ALS drug candidate PAS-004 (opens in a new tab)Compass holds only the headline and link for this source, so the summary below is necessarily brief. Please read the original.
The U.S. Food and Drug Administration granted orphan status to PAS-004, described as a new amyotrophic lateral sclerosis (ALS) drug candidate. The available source does not provide further details about the designation or the candidate.
Why this matters
This concerns the development of PAS-004 for ALS, not a treatment change for people living with the disease. The available information does not establish whether PAS-004 works, is safe, or is available to patients.
Limitations and context
This report is based on the title and metadata of one news article from ALS News Today; its article text was unavailable. No study design, participant data, peer-review status, efficacy results, safety findings, or regulatory details are provided.